Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Masimo's smartSET™ FDA Clearance Offers Breakthrough Innovation in Pulse Oximetry to ...

17 October 2026 · By · Wire by Fusion42

Published

17 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at finance.yahoo.com →

◆ Verified

Fusion42 · 17 October 2026 · Fusion42 review

Masimo received FDA 510(k) clearance for its smartSET pulse oximetry platform featuring AI-enabled atrial fibrillation (AFib) detection alongside opioid-induced respiratory depression (OIRD) monitoring, aimed at providing early clinical insights and improving patient outcomes.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can now integrate AI-powered AFib and opioid risk detection directly into pulse oximetry monitoring to catch patient risks earlier and aid clinical decision-making. This opens a door to build or partner on smarter continuous monitoring tools that deliver more than just vital signs.

◆ Coverage

1 source · 17 Oct 2026

◆ Related on Wire

◆ Topics

MedtechFDA-clearancepulse-oximetryAI-healthtechatrial-fibrillationopioid-monitoring